Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43931   clinical trials with a EudraCT protocol, of which   7307   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2009-012025-11
    Sponsor's Protocol Code Number:01373
    National Competent Authority:Portugal - INFARMED
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2009-12-31
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedPortugal - INFARMED
    A.2EudraCT number2009-012025-11
    A.3Full title of the trial
    A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to evaluate the efficacy and safety of the study drug DP-b99 in patients who suffer from acute ischemic stroke
    A.3.2Name or abbreviated title of the trial where available
    MACSI
    A.4.1Sponsor's protocol code number01373
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT00893867
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorD-Pharm Ltd.
    B.1.3.4CountryIsrael
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportD-Pharm Ltd.
    B.4.2CountryIsrael
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationD-Pharm Ltd.
    B.5.2Functional name of contact pointVP Clinical Development
    B.5.3 Address:
    B.5.3.1Street AddressKiryat Weizmann Science Park
    B.5.3.2Town/ cityRehovot
    B.5.3.3Post code76123
    B.5.3.4CountryIsrael
    B.5.4Telephone number97289385100
    B.5.5Fax number97289300795
    B.5.6E-mailgrosenberg@dpharm.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDP-b99, Lyophilized for Injection, 100mg/vial
    D.3.2Product code DP-b99
    D.3.4Pharmaceutical form Powder for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 222315-66-4
    D.3.9.2Current sponsor codeDP-b99
    D.3.9.3Other descriptive nameDP-BAPTA-99
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPowder for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Acute Ischemic Stroke

    Stroke is the most common neurologic disorder and is the third leading cause of death in developed countries, after myocardial infarction and cancer. Stroke is the second leading cause of neurological morbidity in the United States, Europe, and Japan. 67%- 81% of all stroke cases are ischemic strokes.
    E.1.1.1Medical condition in easily understood language
    Moderately severe stroke
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10055221
    E.1.2Term Ischemic stroke
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to compare the clinical therapeutic effects of intravenous DP-b99 at a dose of 1.0 mg/kg initiated within nine hours of stroke onset and administered daily over 2 hours for 4 consecutive days versus placebo in subjects with moderately severe, likely hemispheric, acute ischemic stroke. The clinical outcome will be measured by the modified Rankin Scale at day 90.
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are to compare the safety and tolerability, as well as post-stroke recovery at Day 90, in subjects treated with DP-b99 versus placebo.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or females 18 to 85 years of age, inclusive

    2. Have suffered an acute, likely hemispheric, ischemic stroke, defined as acute,
    focal, neurological deficit(s), secondary to a presumed vascular event, which
    must include at least one of the following components (as reflected by at least
    1 point on any of the corresponding items of the NIHSS: 3, 9 or 11):
    - Visual
    - Best Language
    - Extinction and Inattention (formerly Neglect)

    3. Have suffered the onset of an acute ischemic stroke that can be evaluated and
    treatment initiated within 9 hours after the onset of acute ischemic stroke
    symptoms. (Onset is defined as the time that the subject was last seen in a
    normal state, or bedtime for unwitnessed strokes occurring during sleep.)

    4. Have at screening a NIHSS score of 10 to 16, inclusive

    5. Have readily accessible peripheral venous access for clinical trial material
    (CTM) administration and blood sampling

    6. Have the ability to understand the requirements of the study and be willing to
    provide written informed consent (IC) as evidenced by signature on an
    informed consent document approved by an institutional review board (IRB)
    or independent ethics committee (IEC), and agree to abide by the study
    restrictions and return for the required assessments. (In the event of
    incapacitated subjects, informed consent will be sought from a legally
    acceptable representative or by any other means as approved by the IRB or
    IEC).
    E.4Principal exclusion criteria
    1. Have an intracerebral or subarachnoid hemorrhage per screening/baseline computerized tomography (CT) scan or susceptibility-weighted magnetic resonance imaging (MRI)

    2. Be a candidate for either:
    a. thrombolytic therapy, or have been treated with thrombolytic therapy for the current stroke
    b. mechanical thromboembolectomy, or have been treated with mechanical thromboembolectomy for the current stroke

    3. Be delirious, comatose or stuporous (a score of ≥2 on item 1.a of the NIHSS) or demented, or having a mental impairment that in the investigator’s opinion renders the subject incapable to participate in the study

    4. Have seizure(s) anytime from stroke onset to screening/baseline NIHSS evaluation

    5. Have neurological or non-neurological comorbidities that in the investigator’s opinion may lead, independent of the current stroke, to further deterioration in the subject’s neurological status during the trial period, or may render the study’s neurological assessments inconclusive for the purpose of evaluating solely the stroke’s effects (e.g., metabolic encephalopathies, hemiplegic migraine, multiple sclerosis, central nervous system tumor, convulsive disorder, monocular blindness)

    6. Be likely to undergo a procedure involving cardiopulmonary bypass during the study period

    7. Have suffered a myocardial infarction in the last 90 days

    8. Have any medical condition that in the investigator’s opinion may threaten the subject’s ability to complete the study (e.g., concurrent significant or life-threatening diseases, such as malignancies or end stage organ failure)

    9. Have rapid spontaneous improvement of neurological signs during screening/baseline assessments

    10. Have premorbid neurological deficits and functional limitations assessed by a pre-stroke Modified Rankin Scale score of > 1

    11. Have suffered a stroke within 90 days of the screening/baseline assessments that is either diagnostically confirmed or assumed to be in the same cerebral territory as is the current acute stroke

    12. Have either severe hypertension (systolic blood pressure (BP) >220 mm Hg or diastolic BP >120 mm Hg) or hypotension (systolic BP <90 mm Hg), as measured by at least 2 consecutive supine measurements taken 10 minutes apart prior to randomization.

    13. Have significant current renal or hepatic disease(s): a serum creatinine concentration of >2.5 mg/dL; alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) values that are three times greater than the upper limit of normal (ULN) (or, if GGT cannot be evaluated, direct bilirubin must not be greater than 1.5 times the ULN).

    14. Have a platelet count of <100,000/mm3 or for patients on oral anticoagulants at study entry, INR of >4

    15. Be a female of childbearing potential (less than 2 years’ postmenopausal or not surgically sterilized) who is not willing to use adequate and effective birth control measures for the duration of the trial. Effective birth control measures include hormonal contraception, a barrier method such as a diaphragm, intrauterine device (IUD) and/or condom with spermicide (IUD, diaphragm, condoms alone or the rhythm method are not considered reliable methods)

    16. Have a positive urine pregnancy test at screening/baseline or be a lactating female

    17. Be currently dependent on, or abusing, alcohol or one or more of the following: sympathomimetic amines (amphetamine-like), cannabis, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives and hypnotics

    18. Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days prior to receiving study medication or have previously participated in a clinical trial involving DP-b99

    19. Have severe anemia as measured by a hemoglobin value of < 7 g/dl.

    20. Being in a dependent relationship with the physician or the study sponsor.

    21. Known hypersensitivity to any component of the investigational product
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is the mRS score at 90 days (or on last rating) following stroke onset as analyzed across the whole distribution of scores (“shift analysis”).
    E.5.1.1Timepoint(s) of evaluation of this end point
    90 days (or on last mRS rating) following stroke onset
    E.5.2Secondary end point(s)
    -Recovery as assessed by an mRS Day 90 score of ≤ 1
    -Recovery as assessed by an NIHSS Day 90 score of ≤ 1
    -The interaction between treatment assignment and time-to-needle in the probability of preventing a negative outcome, i.e., a change to a higher mRS score within 90 days of the stroke
    -"Home Time", the number of nights spent at home/relatives' home between hospital discharge and Day 90
    E.5.2.1Timepoint(s) of evaluation of this end point
    90 days following stroke onset
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA120
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Brazil
    Canada
    Czech Republic
    France
    Germany
    Hungary
    Israel
    Italy
    Korea, Republic of
    Netherlands
    Poland
    Portugal
    Serbia
    Slovakia
    South Africa
    Spain
    Switzerland
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of the trial will be when a total of 770 subjects have been randomized.
    Since this study is monitored by a data safety monitoring board (DSMB), this board may stop the trial early for the following reasons:
    A. Exposure to DP-b99 proves to be unsafe after weighing the pre-determined safety factors as detailed in the DSMB charter
    or
    B. The futility analysis reached its pre-specified futility threshold
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 770
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 770
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Due to the acute ischemic stroke symptoms some patients might not be able to give their consent personally. In such case the informed consent will be sought from a legally acceptable representative or by any other means as approved by the IEC.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state54
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 450
    F.4.2.2In the whole clinical trial 770
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects will be entitled to the normal care, all follow-up plans are detailed in the protocol.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2010-03-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2010-03-05
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2012-02-07
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA